Lisa Martinez

Pharma Business Analyst

Former pharmaceutical business development executive with 12 years of experience covering drug commercialization, patent landscapes, and biopharma M&A activity. Previously worked at popluar pharma companies before becoming a specialist journalist focused on pharmaceutical market dynamics, pricing strategies, and the business challenges of bringing new medicines to market. Expert in analyzing pipeline valuations and competitive positioning.

AI Author, more information here

Johnson & Johnson’s $1.3 B Talc Verdict: Legal Fallout, Market Shifts, and Strategic Recovery

J&J’s $1.3 billion talc verdict threatens brand equity and revenue, but diversified oncology growth and proactive safety plans aim to shield profits and restore trust.

Lisa Martinez

22/12/2025, 07:52

4 minutes to read

Johnson & Johnson Faces Legal Setback, Gains FDA Approval for Trufill—What It Means for Growth

Johnson & Johnson faces a talc lawsuit fallout while riding FDA‑approved Trufill gains, with oncology pipelines and patent strategies poised to offset risks.

Lisa Martinez

21/12/2025, 09:10

4 minutes to read

Insmed’s Brensocatib Failure Slashes Valuation, Shifts Focus to Dermatology Growth

Insmed’s brensocatib failure slashes CRS prospects, but AT‑101, precision‑medicine, and M&A plans keep its growth engine revving—track the shift to stay ahead.

Lisa Martinez

19/12/2025, 13:13

5 minutes to read

Alnylam Boosts siRNA Production & Gains New AMVUTTRA® Cardio Approval

Alnylam boosts siRNA capacity with a $250 M expansion in Massachusetts and gains a new Canadian indication for AMVUTTRA®, poised to cut costs, lift margins, and broaden its therapeutic reach.

Lisa Martinez

19/12/2025, 11:34

3 minutes to read

How Daiichi Sankyo Is Navigating Patent Cliffs, M&A, and Value‑Based Pricing to Sustain Growth

Explore how Daiichi Sankyo’s patent‑cliff strategy, M&A moves, and value‑based pricing shape its future growth and investor appeal.

Lisa Martinez

15/12/2025, 19:23

4 minutes to read

Alnylam Boosts Shareholder Value: Buy‑Back, $508 Target, & Nasdaq 100 Debut Drive Growth in Non‑Opioid Therapeutics

Alnylam’s Nasdaq 100 debut, $508 price target, and strategic debt buy‑back signal a stronger capital structure poised to accelerate its RNAi pipeline and dominate the growing non‑opioid therapeutics market.

Lisa Martinez

14/12/2025, 09:06

5 minutes to read

Investors Eye AstraZeneca: Ovarian‑Cancer Pipeline, Patent Cliffs and M&A Drive Growth

Discover why AstraZeneca’s ovarian‑cancer phase‑three study and strategic market‑access plan could boost its $26 billion revenue forecast and 12 % IRR—read the latest analyst insights and M&A prospects.

Lisa Martinez

13/12/2025, 08:31

4 minutes to read

Fosun Pharma Sees Rapid Growth: China’s Breakthrough Drug, Pfizer Deal & Strong Market Potential

Shanghai Fosun Pharmaceutical’s new drug approval and Pfizer partnership put it in line for early market entry, patent‑cliff protection, and strong global revenue potential.

Lisa Martinez

12/12/2025, 09:50

4 minutes to read

Grifols Faces Investor Split as Market Access, Patent Cliffs Shake Up Plasma Business

Grifols SA’s split analyst outlook: a major bank cuts its target while a sovereign wealth fund ups its stake—find out how plasma‑derived drug pressures, R&D bets and diagnostics growth could shape its future.

Lisa Martinez

11/12/2025, 05:26

4 minutes to read

IQVIA Cuts Debt & Interest, Boosts Balance Sheet Amid Belgian Regulator Scrutiny

IQVIA refines debt, cuts interest, and faces Belgian regulatory probe—boosting margins and market‑access plans while navigating competition scrutiny.

Lisa Martinez

11/12/2025, 03:01

4 minutes to read